Supreme Court opinions are shrinking. But is it a sign of AI taking over the bench, or something far more human? We dig into the 'snippier' trend.
The Supreme Court is wading into a complex patent dispute that could reshape how drug manufacturers protect their innovations from generic competitors. It's not just about labels; it's about the very definition of inducement.
The Supreme Court's big decisions grab headlines, but there's a steady stream of interim actions happening behind the scenes. This week saw justices playing referee on everything from redistricting deadlines to the mifepristone debate.
Virginia's bid to redraw its congressional map in favor of Democrats has hit a dead end at the Supreme Court. The justices offered no explanation, simply turning down the request.
The Supreme Court has issued another temporary reprieve, allowing the abortion pill mifepristone to continue being mailed. This judicial wrangling over access isn't new, and the fight is far from over.
The Fifth Circuit's latest move on abortion pills isn't just a legal footnote; it's a flashing red signal of the ongoing judicial battles reshaping fundamental rights. This isn't about the pills themselves; it's about how far courts are willing to bend established legal principles.
The Supreme Court's term is winding down, and the fate of several crucial patent cases hangs in the balance. Will Section 101 keep swallowing patent law, or will clarity finally emerge?
A $47 million jury hit on Texas ISP Grande Communications? SCOTUS just wiped it clean — for now. Remanded under Cox v. Sony's strict intent test, this could shield neutral pipes from labels' piracy policing demands.
That newborn in the ER, mom undocumented—is she a citizen forever? Oral arguments say no, the 14th Amendment bends like gun rights did for AR-15s.